Company Stock Price of Portola Pharmaceuticals, Inc. (PTLA) Increases 3.17%

Portola Pharmaceuticals, Inc. stock performance trend indicates that the stock price has rallied 57.38% in the past 12 Weeks , but analyzing the 6 month charts for the stock , the price continues to stay positive and keep the rally at 73.67% . Looking at the past 52 week period, the stock price is up at 38.39% . Relative price strength is a important factor used by wealth management firms while investing in stocks because the indicator compares the stock performance with the overall market. The relative price strength of Portola Pharmaceuticals, Inc. has a positive value of 14.69 compared to overall market.Based on the Stock Research the Relative Strength Index signal is in over bought territory with a range of 72.11.

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) has climbed 3.17% in the past week and advanced 24.5% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 2.92% and the outperformance has advanced to 23.08% for the last 4 weeks period.

For the current week, the company shares have a recommendation consensus of Buy. Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) stock ended Friday session in the red zone in a volatile trading. The stock closed down 0.76 points or 1.89% at $39.44 with 1,609,631 shares getting traded. Post opening the session at $39.94, the shares hit an intraday low of $39.14 and an intraday high of $40.168 and the price was in this range throughout the day. The company has a market cap of $2,231 million and the number of outstanding shares has been calculated to be 56,557,396 shares. The 52-week high of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) is $41.27 and the 52-week low is $15.68.

Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Portola Pharmaceuticals Inc was Upgraded by Oppenheimer to Outperform on Feb 24, 2017. Portola Pharmaceuticals Inc was Upgraded by Citigroup to Buy on Jan 3, 2017. Company shares were Reiterated by Credit Suisse on Dec 27, 2016 to Outperform, Raises Price Target to $ 29 from a previous price target of $20 .

Company has reported several Insider transactions to the SEC, on Mar 16, 2017, Mardi Dier (Executive VP and CFO) sold 10,235 shares at 40.02 per share price.On Mar 16, 2017, Charles J Homcy (director) sold 50,000 shares at 40.06 per share price.On May 3, 2016, William Lis (Chief Executive Officer) sold 5,675 shares at 23.86 per share price.

Portola Pharmaceuticals Inc Last issued its quarterly earnings results on Feb 28, 2017. The company reported $-0.95 EPS for the quarter, beating the analyst consensus estimate by $ 0.30. Analyst had a consensus of $-1.25. The company had revenue of $13.70 million for the quarter, compared to analysts expectations of $3.98 million. The companys revenue was up 211.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-1.23 EPS.

Portola Pharmaceuticals, Inc. is a biopharmaceutical company .It focuses on the development and commercialization of therapeutics for thrombosis, other hematologic disorders and inflammation. Portola Pharmaceuticals, Inc. is headquartered in South San Francisco, California.


Leave a Reply

Your email address will not be published. Required fields are marked *